A Risk Assessment Model of Acute Liver Allograft Rejection by Genetic Polymorphism of CD276

Overview

Journal Mol Genet Genomic Med

Specialty Genetics

Date 2019 May 3

PMID 31044564

Citations 3

Authors

Xiaobo Yu

Bajin Wei

Rong Su

Jia Yao

Xiaowen Feng

Guoping Jiang

Haiyang Xie

Jian Wu

Xiao Xu

Min Zhang

Shusen Zheng

Lin Zhou

Affiliations

Soon will be listed here.

Abstract

Background: Liver transplantation is an effective therapy for end-stage liver diseases and acute liver failure. After the operation, however, recipients may suffer grafts loss induced by alloimmune reaction, which is termed as acute allograft rejection. The interaction between costimulatory molecules, CD276, and its ligand, TREML2, promotes T cell-mediated immune response, as well as acute or chronic allograft rejection. Our research aimed at correlating genetic polymorphisms of CD276/TREML2 with acute rejection, and evaluating its prognostic value of acute rejection after liver transplantation.

Methods: The study enrolled a total of 388 recipients. Among them, acute allograft rejection was observed in 54 cases. We performed single nucleotide polymorphism genotyping of CD276, including rs11072431, rs11574495, rs12593558, rs12594627, rs2127015, rs3816661 and rs7176654, and TREML2, including rs4714431, rs6915083, rs7754593, and rs9394767 from preoperative peripheral blood genome DNA.

Results: We found rs2127015 of CD276, rs6915083 and rs7754593 of TREML2, and HBV infection as well were associated with acute rejection. And, rs2127015 influences CD276 expression. Moreover, we established a risk assessment model, composited by statistically proved risk factors.

Conclusion: By integrating both clinical and genetic variables, liver transplant recipients can be categorized into different risk groups, and might benefit from individualized therapies.

Citing Articles

Proteome of Personalized Tissue-Engineered Veins.

Larsson S, Holmgren S, Jenndahl L, Ulfenborg B, Strehl R, Synnergren J ACS Omega. 2024; 9(13):14805-14817.

PMID: 38585136 PMC: 10993322. DOI: 10.1021/acsomega.3c07098.

Importance of genetic polymorphisms in liver transplantation outcomes.

Kelava T, Turcic P, Markotic A, Ostojic A, Sisl D, Mrzljak A World J Gastroenterol. 2020; 26(12):1273-1285.

PMID: 32256016 PMC: 7109269. DOI: 10.3748/wjg.v26.i12.1273.

A risk assessment model of acute liver allograft rejection by genetic polymorphism of CD276.

Yu X, Wei B, Su R, Yao J, Feng X, Jiang G Mol Genet Genomic Med. 2019; 7(6):e689.

PMID: 31044564 PMC: 6603397. DOI: 10.1002/mgg3.689.

References

Leitner J, Klauser C, Pickl W, Stockl J, Majdic O, Bardet A . B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur J Immunol. 2009; 39(7):1754-64. PMC: 2978551. DOI: 10.1002/eji.200839028. View

Xu X, Tu Z, Wang B, Ling Q, Zhang L, Zhou L . A novel model for evaluating the risk of hepatitis B recurrence after liver transplantation. Liver Int. 2011; 31(10):1477-84. DOI: 10.1111/j.1478-3231.2011.02500.x. View

Zhao X, Li D, Zhu X, Gan W, Li Z, Xiong F . B7-H3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2012; 31(2):283-91. PMC: 4042878. DOI: 10.3892/ijmm.2012.1212. View

Hofmeyer K, Ray A, Zang X . The contrasting role of B7-H3. Proc Natl Acad Sci U S A. 2008; 105(30):10277-8. PMC: 2492485. DOI: 10.1073/pnas.0805458105. View

Sawitzki B, Schlickeiser S, Reinke P, Volk H . Monitoring tolerance and rejection in organ transplant recipients. Biomarkers. 2011; 16 Suppl 1:S42-50. DOI: 10.3109/1354750X.2011.578754. View

Hubscher S . Transplantation pathology. Semin Liver Dis. 2009; 29(1):74-90. DOI: 10.1055/s-0029-1192057. View

Marder B, Schroppel B, Lin M, Schiano T, Parekh R, Tomer Y . The impact of costimulatory molecule gene polymorphisms on clinical outcomes in liver transplantation. Am J Transplant. 2003; 3(4):424-31. DOI: 10.1034/j.1600-6143.2003.00084.x. View

Sun J, Chen L, Zhang G, Jiang J, Zhu M, Tan Y . Clinical significance and regulation of the costimulatory molecule B7-H3 in human colorectal carcinoma. Cancer Immunol Immunother. 2010; 59(8):1163-71. PMC: 11030977. DOI: 10.1007/s00262-010-0841-1. View

Yan R, Yang S, Gu A, Zhan F, He C, Qin C . Murine b7-h3 is a co-stimulatory molecule for T cell activation. Monoclon Antib Immunodiagn Immunother. 2013; 32(6):395-8. PMC: 3869539. DOI: 10.1089/mab.2013.0052. View

10.

Yoon B, Chung Y, Yoo S, Kawara K, Kim J, Yoo I . Preferential Induction of the T Cell Auxiliary Signaling Molecule B7-H3 on Synovial Monocytes in Rheumatoid Arthritis. J Biol Chem. 2015; 291(8):4048-57. PMC: 4759181. DOI: 10.1074/jbc.M115.680298. View

11.

Wang L, Kang F, Shan B . B7-H3-mediated tumor immunology: Friend or foe?. Int J Cancer. 2013; 134(12):2764-71. DOI: 10.1002/ijc.28474. View

12.

Wood K, Goto R . Mechanisms of rejection: current perspectives. Transplantation. 2011; 93(1):1-10. DOI: 10.1097/TP.0b013e31823cab44. View

13.

Zheng S, Chen Y, Liang T, Lu A, Wang W, Shen Y . Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl. 2006; 12(2):253-8. DOI: 10.1002/lt.20701. View

14.

Moons K, Kengne A, Woodward M, Royston P, Vergouwe Y, Altman D . Risk prediction models: I. Development, internal validation, and assessing the incremental value of a new (bio)marker. Heart. 2012; 98(9):683-90. DOI: 10.1136/heartjnl-2011-301246. View

15.

Zhu C, Huang Q, Liu C, Xie F . Polymorphisms in the cytotoxic T-lymphocyte antigen 4 gene and acute rejection risk in transplant recipients. Mol Biol Rep. 2012; 39(9):8701-8. DOI: 10.1007/s11033-012-1727-4. View

16.

Yuan H, Wei X, Zhang G, Li C, Zhang X, Hou J . B7-H3 over expression in prostate cancer promotes tumor cell progression. J Urol. 2011; 186(3):1093-9. DOI: 10.1016/j.juro.2011.04.103. View

17.

Hernandez-Fuentes M, Lechler R . A 'biomarker signature' for tolerance in transplantation. Nat Rev Nephrol. 2010; 6(10):606-13. DOI: 10.1038/nrneph.2010.112. View

18.

Chen W, Liu P, Wang Y, Nie W, Li Z, Xu W . Characterization of a soluble B7-H3 (sB7-H3) spliced from the intron and analysis of sB7-H3 in the sera of patients with hepatocellular carcinoma. PLoS One. 2013; 8(10):e76965. PMC: 3806749. DOI: 10.1371/journal.pone.0076965. View

19.

Snanoudj R, Zuber J, Legendre C . Co-stimulation blockade as a new strategy in kidney transplantation: benefits and limits. Drugs. 2010; 70(16):2121-31. DOI: 10.2165/11538140-000000000-00000. View

20.

Ni Y, Chang M . The ways paved for prophylaxis against de novo hepatitis B virus infection after liver transplantation: still many stones left unturned. Pediatr Transplant. 2006; 10(4):405-7. DOI: 10.1111/j.1399-3046.2006.00494.x. View